1,181
Views
0
CrossRef citations to date
0
Altmetric
Foreword

Biologics for psoriasis: is there any unmet need left?

&
Page 1429 | Received 03 Aug 2020, Accepted 28 Sep 2020, Published online: 16 Dec 2022

This very special issue of Expert Opinion on Biological Therapy illustrates the dramatic impact biologics have had on the treatment of psoriasis. Psoriasis is a chronic disease with manifold presentations. Biologics have affected almost every nook and cranny of psoriasis treatment. This issue reviews short- and long-term treatment, use in different psoriasis subpopulations, cost of treatment, and impact of comorbidities, including COVID-19, on patients receiving biologics for psoriasis. While ‘hand holding’ and psychosocial support used to be the most important thing we could offer patients with horrible psoriasis, we now can clear the disease in most patients, nearly clear it in others, and do so with a minimum of risk. Biologics have thoroughly changed the management of this disease, restoring normal quality of life to patients who had been suffering.

Of course, this is only the beginning. We look forward to atopic dermatitis and the rest of dermatology to be transformed by the biologic revolution.

Declaration of interest

S Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate and the National Psoriasis Foundation. He is founder and part owner of Causal Research and holds stock in Sensal Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.